Internal Medicine, Hematology & Oncology · Hammond, LA
NPI
1104883305
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
15752 Medical Arts Plaza, Suite 101
Hammond, LA, 70403
Phone (985) 419-0025
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.2M
201,607 services
Medicare patients, 2024
481
Average age 74
Drug cost, 2024
$8.4M
1,630 prescriptions
Company payments, 2025
$8,477
From 53 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by David N Oubre was code J1439 (injection, ferric carboxymaltose, 1 mg), 33,750 times for 21 patients. In total David N Oubre billed 201,607 services in 102 codes, and Medicare paid $2.2M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-12-22.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 33,750 | 21 | $0.87 | $29K |
| J0897 Injection, denosumab, 1 mg | Office | 5,400 | 22 | $20.31 | $110K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,288 | 26 | $0.09 | $203 |
| J1626 Injection, granisetron hydrochloride, 100 mcg | Office | 1,510 | 22 | $0.25 | $383 |
| 99214 Office E&M - Established | Office | 906 | 314 | $94.54 | $86K |
| 96413 Chemotherapy Administration | Office | 456 | 50 | $96.04 | $44K |
| 96367 Intravenous Infusion, Hydration | Office | 407 | 44 | $21.37 | $8,697 |
| J1200 Injection, diphenhydramine hcl, up to 50 mg | Office | 251 | 32 | $0.64 | $161 |
| 96375 Injection Administration | Office | 245 | 30 | $11.48 | $2,812 |
| 99232 Hospital E&M - Subsequent | Facility | 218 | 73 | $63.21 | $14K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 173 | 155 | $13.05 | $2,258 |
| 96401 Chemotherapy Administration | Office | 137 | 26 | $52.30 | $7,165 |
| 99215 Office E&M - Established | Office | 113 | 76 | $137.94 | $16K |
| 99223 Hospital E&M - Initial | Facility | 112 | 90 | $139.49 | $16K |
| 99213 Office E&M - Established | Office | 93 | 88 | $63.06 | $5,865 |
By year: 2022 $1.8M for 126,353 services; 2023 $1.9M for 110,620 services; 2024 $2.2M for 201,607 services.
Medicare prescription drug claims, 2024
In 2024, the drug David N Oubre prescribed most often to Medicare patients was Anastrozole, with 215 prescriptions and refills. In total David N Oubre wrote 1,630 Medicare prescriptions that cost $8.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 215 | 481 | 57 | $4,677 |
| Tamoxifen Citrate Generic | 72 | 161 | 20 | $2,047 |
| Imatinib Mesylate Generic | 69 | 69 | Under 11 | $151K |
| Abiraterone Acetate Generic | 63 | 63 | Under 11 | $175K |
| Hydroxyurea Generic | 60 | 146 | 19 | $1,969 |
| Eliquis Apixaban | 57 | 57 | Under 11 | $33K |
| Gabapentin Generic | 55 | 55 | 15 | $267 |
| Lenalidomide Generic | 51 | 51 | Under 11 | $648K |
| Imbruvica Ibrutinib | 51 | 51 | Under 11 | $788K |
| Dexamethasone Generic | 50 | 60 | Under 11 | $587 |
| Ibrance Palbociclib | 43 | 43 | Under 11 | $676K |
| Prednisone Generic | 38 | 53 | Under 11 | $152 |
| Ondansetron Odt Ondansetron | 36 | 36 | 16 | $355 |
| Calquence Acalabrutinib Maleate | 34 | 34 | Under 11 | $515K |
| Xtandi Enzalutamide | 29 | 29 | Under 11 | $419K |
Brand drugs: 585 claims; generic drugs: 1,045 claims; opioid claims: 20.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid David N Oubre $8,477 ($7,477 in general payments such as food, travel and fees and $1,000 for research) from 53 companies. The largest payer was Abbvie Inc. with $2,867.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 6 | $2,867 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 6 | $1,401 |
| E.R. Squibb & Sons, L.L.C. BMY | 4 | $1,028 |
| ASD Specialty Healthcare, LLC | 2 | $247 |
| PharmaEssentia USA Corporation 6446.TW | 5 | $222 |
| Novartis Pharmaceuticals Corporation NVS | 10 | $212 |
| Astellas Pharma US Inc 4503.T | 7 | $182 |
| AstraZeneca Pharmaceuticals LP AZN | 8 | $159 |
| Daiichi Sankyo Inc. 4568.T | 5 | $159 |
| Janssen Biotech, Inc. JNJ | 5 | $127 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.